Scroll down to see more

About Laekna

Stock Code: 2105.HK

Founded in 2016, Laekna is a science-driven, clinical-stage biotechnology company committed to bringing novel therapies to cancer and liver fibrosis patients worldwide.

As of June 30, 2023, Laekna has initiated six clinical trials for Afuresertib (LAE002), LAE001 and LAE005 to address unmet medical needs in cancers, such as ovarian cancer, breast cancer and prostate cancer. Among the six clinical trials, three are multi-regional clinical trials (MRCTs) , including one pivotal trial.

Laekna’s internal drug discovery platform has discovered 12 drug candidates. LAE102 is our first internally discovered antibody which has obtained the IND approval from FDA. Its potential indications include muscle regeneration, obesity and cancer.

Laekna, Inc. was listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”) on June 29, 2023, the stock code is 2105.HK.

Our Vision
Our Vision

We are committed to becoming
a biopharmaceutical company
that can bring novel therapies
to cancer and liver fibrosis 
patients worldwide.

Core Management Team
Scientific Advisory Board
Peter ten Dijke
  • Last :Peter ten Dijke
  • Next :Jeff Porter
Core Inverstors
Honors & Awards
  • 2023

    Zhangjiang Life Science Industry New Prominent

  • 2022

    2022 Top 100 Chinese Pharmaceutical Innovation Seed Enterprises

    2022 Pioneers: The Scientists

    KPMG China Future 50 - Biotech

  • 2021

    2021 China Corporate Social Responsibility Virtual Summit - CSR Good Practice

    2021 Top 100 Chinese Pharmaceutical Innovation Seed Enterprises

    Pioneers to the Star 2021 Biomedicine Pioneer-10

    Frost & Sullivan 2021 Top 100 Technology Leaders - Top 50 Innovative Technology Leaders

  • 2020

    Top 20 Disruptive Technologies in Cancer

  • 2019

    China Healthcare Industry Investment and Financing Honor List: Top 20 Emerging Healthcare Companies

  • 2018

    2018 Insights Zhangjiang Top 100

  • 图片10
  • 图片2
  • 图片3
  • 图片4
  • 图片6
  • 图片7
  • 图片8
  • 图片9
  • Last:Peter ten Dijke
  • Next:Jeff Porter
  • Last:Peter ten Dijke
  • Next:Jeff Porter
RSS Feeds
If you want to know more about Laekna, please fill in the form below and sign up for emails:
  1. Name*
  2. Email*
  3. Company
  4. Occupation



Follow us on Linkedin